Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11104MR)

This product GTTS-WQ11104MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11104MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10740MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ8969MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ5117MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ14966MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ2498MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ619MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ11740MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ2760MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG162
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW